In a report released today, Ben Klieve from Lake Street reiterated a Buy rating on AquaBounty Technologies (AQB – Research Report), with a price target of $5.00. The company’s shares opened today at $1.58.
According to TipRanks, Klieve is a 5-star analyst with an average return of 16.5% and a 48.65% success rate. Klieve covers the Basic Materials sector, focusing on stocks such as Bioceres Crop Solutions, MGP Ingredients, and Arcadia Biosciences.
AquaBounty Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
AQB market cap is currently $112.4M and has a P/E ratio of (4.82).
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AQB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AquaBounty Technologies, Inc. is a biotechnology company, which focuses on the enhancement and improvement of the productivity in commercial aquaculture. It uses genetic manipulation and other molecular biologic techniques in order to improve the quality and yield of fish stocks. The company was founded by Elliot Z. Entis and Garth L. Fletcher on December 17, 1991 and is headquartered in Maynard, MA.
Read More on AQB: